Core Insights - Silexion Therapeutics Corp. is attending the 7th RNAi-Based Therapeutics Summit to discuss advancements in RNA-based therapeutics, particularly in oncology [1][2][3] Company Overview - Silexion is a clinical-stage biotechnology company focused on developing treatments for solid tumor cancers associated with mutated KRAS oncogenes, which are prevalent in human cancers [4] - The company is advancing its lead product candidate, SIL204, a next-generation siRNA therapy aimed at silencing mutated KRAS oncogenes, with plans to initiate a Phase 2/3 clinical study in locally advanced pancreatic cancer by mid-2026 [2][4] Event Participation - Silexion management, including CEO Ilan Hadar, will host one-on-one meetings during the RNAi-Based Therapeutics Summit, indicating a proactive approach to engage with potential investors and partners [3] - The company is an official partner of the RNAi-Based Therapeutics Summit for 2026, highlighting its commitment to the field of RNA-based therapeutics [3]